Keywords: allergan, returns, rbpi, rights, xoma, terminated, its
Allergan returns rBPI rights to Xoma
Article | 17 November 2000
Allergan has terminated its agreement with Xoma Corp for the developmentof anti-infective opthalmic products containing recombinant bactericidal/permeability-increasing protein (rBPI). ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
